News

Keytruda (pembrolizumab) reduced the risk of non-small cell lung cancer patients dying by 37 percent, compared with standard chemotherapy, according to updated information from a Phase 3 clinical trial. Sixty-one ... Read more

June 8, 2017June 8, 2017

Alecensa Doubles Time to Disease Progression in Untreated ALK+ NSCLC Patients Compared to Xalkori

News

Genentech’s Alecensa (alectinib) reduced the risk of disease progression or death by 53 percent compared to Xalkori (crizotinib) — the standard of care treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) — concludes ... Read more

June 1, 2017

Trilaciclib Improves Chemo’s Effectiveness Against Small Cell Lung Cancer, Study Finds

News

Adding the CDK4/6 inhibitor trilaciclib to chemotherapy can generate significant benefits for patients with advanced small cell lung cancer (SCLC), according to a Phase 1b/2a clinical trial. Trilaciclib preserved blood ... Read more

May 30, 2017

FDA Gives Green Light to Zykadia as First-line Therapy for ALK-positive NSCLC

News

The U.S. Food and Drug Administration has approved Norvartis‘ Zykadia (ceritinib) to be used as first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ... Read more

May 25, 2017

EU Panel Recommends Approval of Zykadia as First-line Treatment for ALK-Positive NSCLC

News

Zykadia (ceritinib) was recommended for approval in Europe by the EMA‘s Committee for Medicinal Products for Human Use (CHMP) as first-line treatment for patients with advanced non-small cell lung cancer ... Read more

May 23, 2017

Ventilation Holes in Cigarette Filters Have Increased Lung Cancer, Study Reports

News

The light cigarettes that the tobacco industry markets as healthier have actually increased lung cancer, according to a study. That’s because the ventilation holes the industry began adding to ... Read more

May 18, 2017

Phase 3 Trial Shows Promising Results for Imfinzi in Subset of NSCLC Patients

News

Patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) who have not progressed following standard platinum-based chemotherapy and radiation therapy, may greatly benefit from treatment with the PD-L1 ... Read more

May 16, 2017

Alunbrig Shows Promise in Certain Advanced NSCLC Patients with ALK Mutations, Study Reports

News

Takeda’s Alunbrig (brigatinib) has shown promise in treating ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who either progressed with — or could not tolerate treatment with — Xalkori ... Read more

May 12, 2017May 12, 2017

FDA Puts Keytruda on Accelerated Approval Track as Combo Lung Cancer Treatment

News

The U.S. Food and Drug Administration has put Merck‘s Keytruda (pembrolizumab) on an accelerated approval track as a combo treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The accelerated ... Read more

May 11, 2017May 11, 2017

Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer

News

Biocept and the Addario Lung Cancer Medical Institute (ALCMI) will collaborate on a clinical study assessing the efficacy of Biocept’s Target Selector platform to detect circulating biomarkers in patients with ... Read more